Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer

le of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer Review (4356) Total Article Views Authors: Jochen H Lorch Published Date November 2009 Volume 2009:1 Pages 151 - 154 DOI: http://dx.doi.org/10.2147/CMAR.S5134 Jochen H Lorch Dana Farber Cancer institute, Boston, MA, USA Abstract: Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCHN both in the up-front treatment and in the recurrent and metastatic setting. This review summarizes the most important developments of the recent past and provides an overview of newer developments.